Appendix Table 5.
Clinical Characteristics of MrOS Sleep Participants by CKD-EPIcysc eGFR Category
| CKD-EPIcysc eGFR category (mL/min/1.73m2)
|
||||||
|---|---|---|---|---|---|---|
| Baseline Characteristics | Overall (N= 2994) |
≥75 (N= 1078) |
60 to 74 (N= 826) |
45 to 59 (N= 691) |
<45 (N= 399) |
p-value |
| Age, years, mean (SD) | 76.4 (5.6) | 74.0 (4.6) | 76.1 (5.0) | 78.1 (5.4) | 80.3 (6.1) | <0.001 |
| Race/Ethnicity, n (%) | <0.001 | |||||
| White | 2696 (90) | 927 (86) | 763 (93) | 643 (93) | 363 (91) | |
| Black | 109 (4) | 54 (5) | 23 (3) | 20 (3) | 12 (3) | |
| Other | 189 (6) | 97 (9) | 40 (5) | 28 (4) | 24 (6) | |
| Education, n (%) | <0.001 | |||||
| Less than high school | 160 (5) | 49 (5) | 31 (4) | 43 (6) | 37 (9) | |
| High school | 472 (16) | 140 (13) | 115 (14) | 146 (21) | 71 (18) | |
| College/grad school | 2362 (79) | 889 (82) | 680 (82) | 502 (73) | 291 (73) | |
| Body mass index, kg/m2, mean (SD) | 27.2 (3.8) | 26.6 (3.4) | 27.4 (3.9) | 27.5 (3.9) | 27.8 (4.4) | <0.001 |
| Appendicular lean mass, kg, mean (SD) | 23.9 (3.5) | 24.2 (3.3) | 24.1 (3.4) | 23.8 (3.5) | 23.1 (3.6) | <0.001 |
| Total body lean mass, kg, mean (SD) | 56.3 (7.1) | 56.6 (6.8) | 56.6 (7.2) | 56.3 (7.3) | 55.3 (7.4) | 0.014 |
| Smoking, n (%) | ||||||
| Never | 1183 (40) | 426 (40) | 350 (42) | 267 (39) | 140 (35) | 0.019 |
| Past | 1750 (58) | 639 (59) | 462 (56) | 400 (58) | 249 (62) | |
| Current | 59 (2) | 13 (1) | 14 (2) | 22 (3) | 10 (3) | |
| Self-rated health good/excellent, n (%) | 2596 (87) | 989 (92) | 727 (88) | 580 (84) | 300 (75) | <0.001 |
| Hypertension*, n (%) | 1894 (63) | 548 (51) | 491 (59) | 495 (72) | 360 (90) | <0.001 |
| Diabetes*, n (%) | 402 (13) | 131 (12) | 96 (12) | 87 (13) | 88 (22) | <0.001 |
| Self-reported stroke, n (%) | 110 (4) | 31 (3) | 21 (3) | 29 (4) | 29 (7) | <0.001 |
| Self-reported coronary heart disease**, n (%) | 765 (26) | 185 (17) | 215 (26) | 201 (29) | 164 (41) | <0.001 |
| Self-reported congestive heart failure, n (%) | 181 (6) | 27 (3) | 43 (5) | 48 (7) | 63 (16) | <0.001 |
| Self-reported peripheral vascular disease, n (%) | 291 (10) | 63 (6) | 64 (8) | 79 (12) | 85 (22) | <0.001 |
| Alcohol intake, drinks/week, n (%) | <0.001 | |||||
| 0–2 | 1761 (59) | 560 (52) | 470 (57) | 444 (65) | 287 (72) | |
| 3–13 | 1048 (35) | 426 (40) | 313 (38) | 212 (31) | 97 (24) | |
| 14+ | 168 (6) | 85 (8) | 41 (5.0) | 29 (4) | 13 (3) | |
| CKD-EPIcr,cys eGFR, mean (SD) | 69.8 (17.1) | 86.7 (8.7) | 70.8 (5.9) | 58.5 (6.1) | 41.9 (8.7) | <0.001 |
| BIS2 eGFR, mean (SD) | 62.4 (13.6) | 75.8 (8.0) | 62.9 (4.5) | 53.4 (4.4) | 40.8 (6.7) | <0.001 |
| CKD-EPIcys eGFR, mean (SD) | 67.8 (19.8) | 89.1 (9.9) | 67.3 (4.3) | 53.1 (4.0) | 36.9 (7.0) | <0.001 |
| CKD-EPIcr eGFR, mean (SD) | 70.7 (14.9) | 81.1 (9.6) | 73.1 (9.9) | 64.2 (10.9) | 48.7 (12.7) | <.001 |
| Follow up time, years, mean (SD) | 7.3 (1.9) | 7.7 (1.5) | 7.4 (1.9) | 7.2 (2.0) | 6.1 (2.5) | <0.001 |
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; cr, creatinine; cysc, cystatin c; eGFR, estimated glomerular filtration rate; BIS2, Berlin Initiative Study Equation 2
*
As determined by self-report or any disease-specific medication use
**
Coronary heart disease includes myocardial infarction, coronary artery bypass grafting, and angioplasty